Risk factor
Very poor trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Shanghai HeartCare Medical Technology Corporation Limited engages in the research, development, manufacture, and sale of neuro-interventional medical devices worldwide. The company offers ischemic stroke thrombectomy, intracranial stenosis treatment, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access devices. Its products are used for the treatment and prevention of ischemic stroke, including acute ischemic stroke and...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued
Target Price
The average target price of 6609.HK is 20 and suggests 57% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to de
Buy
Sell